OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
Category: #health  By Mateen Dalal  Date: 2020-07-18
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19.

As per the latest news, France-based OSE Immunotherapeutics has reportedly announced that it has obtained an additional grant of up to USD 228,000 for the development of a prophylactic vaccine to treat the COVID-19.

Sources cite that the grant is a part of the USD 1.14 million ‘Metropolitan Fund’ which was created by Nantes Metropole for health innovations that can tackle the COVID-19 health crisis. The company is working actively on the development of the SARS-CoV-2 prophylactic vaccine. This research program seeks the development of a vaccine, which is based on a multi-epitope peptide approach and focuses on memory T cells.

The firm uses its expertise in the selection and optimization of peptides related to disease to increase the T lymphocyte's memory response against specific antigens using its established optimization technology for neo-epitopes.

OSE Immunotherapeutics’ research and development team screened a large number of peptides from the various proteins of SARS-CoV- 2, SARS-CoV and MERS-CoV with the help of a bioinformatics approach and algorithms for predicting immunogenicity of the virus Genome and has selected immunodominant epitopes from eight major proteins.

For the record, more than 10 million have been infected by COVID-19 while over half a million people lost their lives. While more than seven million COVID-19 patients have recovered so far, researchers worldwide are trying to scale the development and production of a potential COVID-19 as soon as possible. 

Meanwhile, Russian scientists have also claimed that they would roll out the first batch of vaccines by mid-August. Sources cite that a small amount of the COVID-19 vaccine would be available to patients in the middle of August, and private companies would start production of vaccines in September.

Source Credit - https://www.benzinga.com/pressreleases/20/07/g16645378/ose-immunotherapeutics-receives-200-000-from-nantes-metropole-to-develop-covepit-its-covid-19-prop

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...